StockNews.AI
MDT
StockNews.AI
182 days

Medtronic reports third quarter fiscal 2025 financial results

1. Medtronic's Q3 revenue grew 2.5%, driven by strong performance in key product areas. 2. GAAP EPS increased 2%, reinforcing growth expectations in ongoing treatments like PFA.

2m saved
Insight
Article

FAQ

Why Bullish?

The revenue and EPS growth indicates solid operational performance, aligning with MDT's market position. Past examples include improvements following strong quarterly reports boosting investor confidence.

How important is it?

The article highlights essential financial performance and future expectations, directly affecting investor sentiment and potential price movement.

Why Short Term?

The immediate positive financial indicators suggest short-term price benefits, similar to prior results stimulating quick investor reactions.

Related Companies

MDTABTSYK
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland , Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported and 4.1% organic GAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7% Company reiterates full year revenue and EPS guidance Cardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) products U.S. Centers for Medicare and Medicaid (CMS) announced coverage for Renal Denervation for the treatment of Hypertension expected to become final on or before October 11, 2025 Financial Results Medtronic reported Q3 worldwide revenue of $8.292 billion, an increase of 2.5% as reported and 4.1% on an organic basis.

Related News